Yali Liu
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.
Dal Pra A, Ghadjar P, Hayoz S, Liu V, Spratt D, Thompson D, Davicioni E, Huang H, Zhao X, Liu Y, Scharf C, Gut P, Plasswilm L, Hölscher T, Polat B, Hildebrandt G, Müller A, Pollack A, Thalmann G, Zwahlen D, Aebersold D. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial. Ann Oncol 2022; 33:950-958.
May 28, 2022Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.
May 28, 2022Ann Oncol 2022; 33:950-958
Dal Pra Alan, Ghadjar Pirus, Hayoz S, Liu V Y T, Spratt D E, Thompson D J S, Davicioni E, Huang H-C, Zhao X, Liu Yali, Scharf Christop, Gut P, Plasswilm Ludwig, Hölscher Tobias, Polat Bülent, Hildebrandt G, Müller A-C, Pollack A, Thalmann G N, Zwahlen D, Aebersold D M
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Heinhuis K, Schilder R, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Britschgi C, Paz-Ares L, Carlino M, Jörger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord J, Siu L. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. JAMA Oncol 2019:1-8.
Nov 7, 2019Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Nov 7, 2019JAMA Oncol 2019:1-8
Heinhuis Kimberley M, Schilder Russell J, O'Byrne Kenneth, Curigliano Giuseppe, Romano Emanuela, Patah Poliana, Wang Rui, Liu Yali, Bajaj Gaurav, Britschgi Christian, Paz-Ares Luis, Carlino Matteo, Jörger Markus, Di Nicola Massimo, Meniawy Tarek, Rottey Sylvie, Moreno Victor, Gazzah Anas, Delord Jean-Pierre, Siu Lillian L